Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease

Stephen P. Gray*, Jay C. Jha, Kit Kennedy, Erik van Bommel, Phyllis Chew, Cedric Szyndralewiez, Rhian M. Touyz, Harald H. H. W. Schmidt, Mark E. Cooper, Karin A. M. Jandeleit-Dahm

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)927-937
Number of pages11
JournalDiabetologia
Volume60
Issue number5
DOIs
Publication statusPublished - May 2017

Keywords

  • Atherosclerosis
  • Diabetes
  • NADPH oxidase
  • Nephropathy
  • Oxidative stress
  • DIABETES-ASSOCIATED ATHEROSCLEROSIS
  • NADPH OXIDASE
  • ACCELERATED ATHEROSCLEROSIS
  • PHARMACOLOGICAL INHIBITION
  • OXIDATIVE STRESS
  • BLOOD-PRESSURE
  • KNOCKOUT MICE
  • MOUSE MODEL
  • KEY ROLE
  • RENOPROTECTION

Cite this

Gray, S. P., Jha, J. C., Kennedy, K., van Bommel, E., Chew, P., Szyndralewiez, C., Touyz, R. M., Schmidt, H. H. H. W., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2017). Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia, 60(5), 927-937. https://doi.org/10.1007/s00125-017-4215-5